Oct 12 2026 09:49 PM EST
Haemonetics Shares Surge on CSL Supply Deal and Citi Upgrade
Shares of Haemonetics Corporation (NYSE: HAE) leapt 15.96% on Thursday, touching an intraday high of $121 and closing near $118. The move followed CSL Plasma’s announcement that it will deploy Haemonetics’ NexSys PCS devices with Persona PLUS technology across all U.S. plasma collection centers by the end of 2027, and a concurrent upgrade by Citigroup from Neutral to Buy.
Citigroup raised its price target to $123 (up from $92) and cited the CSL non‑exclusive supply agreement as a direct earnings catalyst, estimating that each 10 % share recapture in the CSL business adds roughly $0.13 to earnings per share. In the same week, Haemonetics received a $6.1 million milestone payment from Orchestra BioMed, completing the $11 million upfront consideration for the Vivasure acquisition and unlocking up to $10 million in future earn‑outs.
CSL Supply Agreement Fuels Immediate Rally
The non‑exclusive contract gives Haemonetics a recurring‑revenue stream as CSL rolls out NexSys PCS devices, which incorporate the Persona PLUS disposable set that delivers a mid‑single‑digit yield uplift per donation. Management projects that each 10 % increase in CSL‑related volume translates into an EPS boost of about $0.13, a material contribution given the company’s FY 2026 adjusted EPS of $4.96.
Financial Profile Supports Upside
Haemonetics reported Q1 FY2027 revenue of $339.4 million, beating consensus by 3.1 %, and adjusted EPS of $1.14, modestly above the estimate of $1.09. Gross margins remain strong at roughly 59 %, while adjusted operating margin sits near 26 %. Free cash flow generated in the quarter was about $44 million, underscoring the company’s ability to fund share repurchases and strategic investments.
Sector and Macro Context
Automated plasma collection now accounts for roughly 68.9 % of the U.S. market, and the global plasma market is projected to grow at a 7.2 % CAGR through 2034. These trends bolster Haemonetics’ recurring‑revenue model, as demand for plasma‑derived therapies is expected to rise 6‑8 % annually, driven by oncology and hemophilia treatment needs.
Strategic Outlook and Valuation
Management reaffirmed FY 2027 revenue growth guidance of 4 %–7 % reported (3 %–6 % organic) and expects operating‑margin expansion of 50–100 basis points. The forward P/E of roughly 12 × (based on FY 2026 adjusted EPS) suggests the stock is priced above its historical median, but the upgraded Citi target of $123 implies investors are pricing in the CSL upside and the Vivasure earn‑out potential.
Risks and Uncertainties
Key risks include the execution timeline of the CSL rollout, which could be delayed by supply‑chain constraints or regulatory approvals; potential litigation with competitors over plasma‑device patents; and the contingent nature of the Vivasure earn‑outs, which depend on successful market adoption of the PerQseal Elite closure system. Additionally, the company’s leverage—net debt of roughly $1.2 billion—remains elevated, though interest coverage exceeds 20 ×.